Insider Selling: Twist Bioscience (NASDAQ:TWST) CAO Sells $20,039.20 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CAO Robert Werner sold 148 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total value of $20,039.20. Following the completion of the sale, the chief accounting officer owned 42,769 shares of the company’s stock, valued at $5,790,922.60. This trade represents a 0.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Trading Up 0.1%

NASDAQ TWST opened at $120.79 on Friday. The firm has a market cap of $7.57 billion, a P/E ratio of -54.41 and a beta of 2.25. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The stock’s 50-day moving average is $151.35 and its 200-day moving average is $91.08. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $219.71.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TWST. BWS Financial reaffirmed a “sell” rating and issued a $45.00 price target on shares of Twist Bioscience in a research note on Friday, September 18th. Barclays increased their price objective on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. UBS Group began coverage on shares of Twist Bioscience in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price objective on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Twist Bioscience in a research note on Thursday, October 8th. They issued a “hold” rating and a $150.00 target price for the company. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $153.00.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently added to or reduced their stakes in TWST. BlackRock Inc. bought a new stake in Twist Bioscience during the second quarter worth $600,191,000. William Blair Investment Management LLC acquired a new stake in Twist Bioscience in the second quarter valued at $223,722,000. Bank of America Corp DE bought a new position in shares of Twist Bioscience in the 2nd quarter valued at about $94,922,000. Russell Investments Group Ltd. grew its position in shares of Twist Bioscience by 190.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 283,910 shares of the company’s stock valued at $54,863,000 after acquiring an additional 186,294 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Twist Bioscience in the 1st quarter valued at about $22,563,000.

Trending Headlines about Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist launched MRD Express, potentially expanding its presence in minimal residual disease testing. Investors may look for further details on the product and business outlook around earnings. Article: Twist Bioscience stock enters earnings week after MRD Express launch
• Neutral Sentiment: CEO Emily Leproust and three other insiders sold a combined 6,677 shares at $135.40. The sales were disclosed as covering tax withholding on equity-award vesting, and each seller retained a substantial stake.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The provided article headline does not specify the report’s allegations, but its release appears to have hurt sentiment. Article: Twist Bioscience falls amid negative report

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications.

The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

Founded in 2013 and headquartered in South San Francisco, California, Twist serves customers in biotechnology, pharmaceutical, academic, agricultural and other industries around the world.